Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin

Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin

Khai-Jing Ng,1,2,* Chih-Wei Tseng,1–4,* Ting-Tsung Chang,5,6 Shinn-Jia Tzeng,7 Yu-Hsi Hsieh,1,2 Tsung-Hsing Hung,1,2 Hsiang-Ting Huang,8 Shu-Fen Wu,9 Kuo-Chih Tseng1,2 1Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, 2School of Medici...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ng KJ, Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
aspartate aminotransferase to platelet ratio index
chronic hepatitis C
hepatitis C virus
hepatocellular carcinoma
liver cirrhosis
sustained virologic response
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/a97a3d489c3d4fcc89c510b2b74c18bb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a97a3d489c3d4fcc89c510b2b74c18bb
record_format dspace
spelling oai:doaj.org-article:a97a3d489c3d4fcc89c510b2b74c18bb2021-12-02T05:13:03ZAspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin1178-1998https://doaj.org/article/a97a3d489c3d4fcc89c510b2b74c18bb2016-08-01T00:00:00Zhttps://www.dovepress.com/aspartate-aminotransferase-to-platelet-ratio-index-and-sustained-virol-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Khai-Jing Ng,1,2,* Chih-Wei Tseng,1–4,* Ting-Tsung Chang,5,6 Shinn-Jia Tzeng,7 Yu-Hsi Hsieh,1,2 Tsung-Hsing Hung,1,2 Hsiang-Ting Huang,8 Shu-Fen Wu,9 Kuo-Chih Tseng1,2 1Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, 2School of Medicine, Tzu Chi University, Hualien, 3Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, 4School of Medicine, National Yang-Ming University, Taipei, 5Department of Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, 6Infectious Disease and Signaling Research Center, National Cheng Kung University, Tainan, 7Department of Agronomy, National Chiayi University, Chia-Yi, 8Department of Nursing, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, 9Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan *These authors contributed equally to this work Background: The aim of this study was to evaluate the clinically significant predictors of hepatocellular carcinoma (HCC) development among hepatitis C virus (HCV) cirrhotic patients receiving combination therapy.Patients and methods: One hundred and five compensated cirrhosis patients who received pegylated interferon plus ribavirin between January 2005 and December 2011 were enrolled. All the patients were examined with abdominal sonography and liver biochemistry at baseline, end of treatment, and every 3–6 months posttreatment. The occurrence of HCC was evaluated every 3–6 months posttreatment.Results: A total of 105 patients were enrolled (mean age 58.3±10.4 years). The average follow-up time for each patient was 4.38 years (standard deviation 1.73 years; range 1.13–9.27 years). Fifteen (14.3%) patients developed HCC during follow-up period. Thirteen of them had high baseline aspartate aminotransferase to platelet ratio index (APRI) (ie, an APRI >2.0). Multivariate analysis showed that those without sustained virologic response (SVR) (hazard ratio [HR] 5.795; 95% confidence interval [CI] 1.370–24.5; P=0.017) and high APRI (HR 5.548; 95% CI 1.191–25.86; P=0.029) had a significantly higher risk of HCC occurrence. The cumulative incidence of HCC was significantly higher (P=0.009) in patients without SVR (3-year cumulative incidence 21.4%; 95% CI 7.4%–35.5%; 5-year cumulative incidence 31.1%; 95% CI 11.2%–51.1%) compared to those with SVR (3- and 5-year cumulative incidence 6.2%; 95% CI 0%–1.3%). Further, the cumulative incidence of HCC was significantly higher (P=0.006) in patients with high APRI (3-year cumulative incidence 21.8%; 95% CI 8.2%–35.3%; 5-year cumulative incidence 30.5%, 95% CI 11.8%–49.3%) compared to those with low APRI (3- and 5-year cumulative incidence 4.2%, 95% CI 0%–1.0%).Conclusion: In HCV-infected cirrhotic patients who received combination therapy, APRI and SVR are the two major predictors of HCC development. Keywords: aspartate aminotransferase to platelet ratio index, chronic hepatitis C, hepatitis C virus, hepatocellular carcinoma, liver cirrhosis, sustained virologic responseNg KJTseng CWChang TTTzeng SJHsieh YHHung THHuang HTWu SFTseng KCDove Medical Pressarticleaspartate aminotransferase to platelet ratio indexchronic hepatitis Chepatitis C virushepatocellular carcinomaliver cirrhosissustained virologic responseGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 11, Pp 1035-1041 (2016)
institution DOAJ
collection DOAJ
language EN
topic aspartate aminotransferase to platelet ratio index
chronic hepatitis C
hepatitis C virus
hepatocellular carcinoma
liver cirrhosis
sustained virologic response
Geriatrics
RC952-954.6
spellingShingle aspartate aminotransferase to platelet ratio index
chronic hepatitis C
hepatitis C virus
hepatocellular carcinoma
liver cirrhosis
sustained virologic response
Geriatrics
RC952-954.6
Ng KJ
Tseng CW
Chang TT
Tzeng SJ
Hsieh YH
Hung TH
Huang HT
Wu SF
Tseng KC
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
description Khai-Jing Ng,1,2,* Chih-Wei Tseng,1–4,* Ting-Tsung Chang,5,6 Shinn-Jia Tzeng,7 Yu-Hsi Hsieh,1,2 Tsung-Hsing Hung,1,2 Hsiang-Ting Huang,8 Shu-Fen Wu,9 Kuo-Chih Tseng1,2 1Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, 2School of Medicine, Tzu Chi University, Hualien, 3Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, 4School of Medicine, National Yang-Ming University, Taipei, 5Department of Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, 6Infectious Disease and Signaling Research Center, National Cheng Kung University, Tainan, 7Department of Agronomy, National Chiayi University, Chia-Yi, 8Department of Nursing, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, 9Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan *These authors contributed equally to this work Background: The aim of this study was to evaluate the clinically significant predictors of hepatocellular carcinoma (HCC) development among hepatitis C virus (HCV) cirrhotic patients receiving combination therapy.Patients and methods: One hundred and five compensated cirrhosis patients who received pegylated interferon plus ribavirin between January 2005 and December 2011 were enrolled. All the patients were examined with abdominal sonography and liver biochemistry at baseline, end of treatment, and every 3–6 months posttreatment. The occurrence of HCC was evaluated every 3–6 months posttreatment.Results: A total of 105 patients were enrolled (mean age 58.3±10.4 years). The average follow-up time for each patient was 4.38 years (standard deviation 1.73 years; range 1.13–9.27 years). Fifteen (14.3%) patients developed HCC during follow-up period. Thirteen of them had high baseline aspartate aminotransferase to platelet ratio index (APRI) (ie, an APRI >2.0). Multivariate analysis showed that those without sustained virologic response (SVR) (hazard ratio [HR] 5.795; 95% confidence interval [CI] 1.370–24.5; P=0.017) and high APRI (HR 5.548; 95% CI 1.191–25.86; P=0.029) had a significantly higher risk of HCC occurrence. The cumulative incidence of HCC was significantly higher (P=0.009) in patients without SVR (3-year cumulative incidence 21.4%; 95% CI 7.4%–35.5%; 5-year cumulative incidence 31.1%; 95% CI 11.2%–51.1%) compared to those with SVR (3- and 5-year cumulative incidence 6.2%; 95% CI 0%–1.3%). Further, the cumulative incidence of HCC was significantly higher (P=0.006) in patients with high APRI (3-year cumulative incidence 21.8%; 95% CI 8.2%–35.3%; 5-year cumulative incidence 30.5%, 95% CI 11.8%–49.3%) compared to those with low APRI (3- and 5-year cumulative incidence 4.2%, 95% CI 0%–1.0%).Conclusion: In HCV-infected cirrhotic patients who received combination therapy, APRI and SVR are the two major predictors of HCC development. Keywords: aspartate aminotransferase to platelet ratio index, chronic hepatitis C, hepatitis C virus, hepatocellular carcinoma, liver cirrhosis, sustained virologic response
format article
author Ng KJ
Tseng CW
Chang TT
Tzeng SJ
Hsieh YH
Hung TH
Huang HT
Wu SF
Tseng KC
author_facet Ng KJ
Tseng CW
Chang TT
Tzeng SJ
Hsieh YH
Hung TH
Huang HT
Wu SF
Tseng KC
author_sort Ng KJ
title Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
title_short Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
title_full Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
title_fullStr Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
title_full_unstemmed Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
title_sort aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis c associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/a97a3d489c3d4fcc89c510b2b74c18bb
work_keys_str_mv AT ngkj aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
AT tsengcw aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
AT changtt aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
AT tzengsj aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
AT hsiehyh aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
AT hungth aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
AT huanght aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
AT wusf aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
AT tsengkc aspartateaminotransferasetoplateletratioindexandsustainedvirologicresponseareassociatedwithprogressionfromhepatitiscassociatedlivercirrhosistohepatocellularcarcinomaaftertreatmentwithpegylatedinterferonplusribavirin
_version_ 1718400490581000192

Ejemplares similares